Search Results

BridgePoint Commences Trial of CTO Devices

March 11, 2009—BridgePoint Medical, Inc. (Minneapolis, MN) announced the commencement of enrollment in a clinical investigation of the company's devices for the treatment of chronic total occlusions (CTOs).

BridgePoint's CrossBoss and Stingray Clearance Expanded to Treat CTOs

May 16, 2011—BridgePoint Medical, Inc. (Plymouth, MN) announced that the company has received US Food and Drug Administration (FDA) clearance for an expanded indication for the CrossBoss catheter and Stingray system.

Reflow Medical Commences DEEPER CORONARY Pilot Study of Spur Elute Retrievable Scaffold

July 1, 2024—Reflow Medical, Inc. announced that the first patients were enrolled in DEEPER CORONARY, a pilot study of the company’s Spur Elute sirolimus-eluting retrievable scaffold system as a primary treatment for in-stent restenosis (ISR) of the coronary arteries.

Reflow Launches CoraCatheters Line of Microcatheters for Complex PCI

May 18, 2023—Reflow Medical, Inc. announced that it has received FDA clearance for its CoraCatheters line of microcatheters that are designed to access and cross complex and challenging lesions in percutaneous coronary intervention (PCI).

FDA Approves TriReme's Glider PTCA Catheter

May 23, 2012—TriReme Medical, Inc. (Pleasanton, CA) announced approval by the US Food and Drug Administration (FDA) of the company's Glider percutaneous transluminal coronary angioplasty (PTCA) catheter, indicated for treating the stenotic portion of coronary arteries or bypass grafts to improve myocardial perfusion.